tiprankstipranks
Trending News
More News >
Abattis Bioceuticals Corp (ATTBF)
OTHER OTC:ATTBF
US Market

Abattis Bioceuticals (ATTBF) Ratios

Compare
175 Followers

Abattis Bioceuticals Ratios

ATTBF's free cash flow for Q4 2019 was C$0.72. For the 2019 fiscal year, ATTBF's free cash flow was decreased by C$ and operating cash flow was C$-3.93. See a summary of the company’s cash flow.
Ratios
TTM
Sep 19Sep 18Sep 17
Liquidity Ratios
Current Ratio
0.73 0.73 34.51
Quick Ratio
0.68 0.68 34.41
Cash Ratio
0.41 0.41 13.41
Solvency Ratio
-0.34 -0.34 -257.21
Operating Cash Flow Ratio
1.92 1.92 -27.31
Short-Term Operating Cash Flow Coverage
6.64 6.64 0.00
Net Current Asset Value
C$ -4.99MC$ -4.99MC$ 10.16M
Leverage Ratios
Debt-to-Assets Ratio
0.08 0.08 0.00
Debt-to-Equity Ratio
0.14 0.14 0.00
Debt-to-Capital Ratio
0.12 0.12 0.00
Long-Term Debt-to-Capital Ratio
0.00 0.00 0.00
Financial Leverage Ratio
1.74 1.74 0.99
Debt Service Coverage Ratio
-1.98 -1.98 -4.73
Interest Coverage Ratio
-80.16 -80.16 -4.01
Debt to Market Cap
72.92 0.13 0.00
Interest Debt Per Share
<0.01 <0.01 0.01
Net Debt to EBITDA
0.15 0.15 0.23
Profitability Margins
Gross Profit Margin
67.62%67.62%77.37%
EBIT Margin
-843.89%-843.89%-875805.50%
EBITDA Margin
-813.34%-813.34%-207095.93%
Operating Profit Margin
-1108.73%-1108.73%-207542.23%
Pretax Profit Margin
-857.72%-857.72%-927614.02%
Net Profit Margin
-852.40%-852.40%-931940.11%
Continuous Operations Profit Margin
-857.72%-857.72%-927614.02%
Net Income Per EBT
99.38%99.38%100.47%
EBT Per EBIT
77.36%77.36%446.95%
Return on Assets (ROA)
-15.79%-15.79%-684.35%
Return on Equity (ROE)
-26.96%-27.46%-679.12%
Return on Capital Employed (ROCE)
-27.58%-27.58%-156.57%
Return on Invested Capital (ROIC)
-25.05%-25.05%-156.57%
Return on Tangible Assets
-68.98%-68.98%-684.35%
Earnings Yield
-15870.32%-26.98%-135.47%
Efficiency Ratios
Receivables Turnover
2.30 2.30 0.00
Payables Turnover
0.53 0.53 <0.01
Inventory Turnover
0.43 0.43 0.06
Fixed Asset Turnover
0.47 0.47 0.01
Asset Turnover
0.02 0.02 <0.01
Working Capital Turnover Ratio
0.08 0.08 <0.01
Cash Conversion Cycle
310.19 310.19 -37.21K
Days of Sales Outstanding
158.61 158.61 0.00
Days of Inventory Outstanding
846.07 846.07 5.87K
Days of Payables Outstanding
694.49 694.49 43.08K
Operating Cycle
1.00K 1.00K 5.87K
Cash Flow Ratios
Operating Cash Flow Per Share
0.02 0.02 -0.03
Free Cash Flow Per Share
<0.01 <0.01 -0.03
CapEx Per Share
0.01 0.01 <0.01
Free Cash Flow to Operating Cash Flow
0.46 0.46 1.03
Dividend Paid and CapEx Coverage Ratio
1.86 1.86 -35.42
Capital Expenditure Coverage Ratio
1.86 1.86 -35.42
Operating Cash Flow Coverage Ratio
6.00 6.00 0.00
Operating Cash Flow to Sales Ratio
26.37 26.37 -989.06
Free Cash Flow Yield
22353.74%38.59%-14.78%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
>-0.01 -3.71 -0.74
Price-to-Sales (P/S) Ratio
0.05 31.59 6.88K
Price-to-Book (P/B) Ratio
<0.01 1.02 5.01
Price-to-Free Cash Flow (P/FCF) Ratio
<0.01 2.59 -6.76
Price-to-Operating Cash Flow Ratio
<0.01 1.20 -6.96
Price-to-Earnings Growth (PEG) Ratio
>-0.01 0.04 >-0.01
Price-to-Fair Value
<0.01 1.02 5.01
Enterprise Value Multiple
0.15 -3.73 -3.09
Enterprise Value
-430.37K 10.83M 53.52M
EV to EBITDA
0.15 -3.73 -3.09
EV to Sales
-1.21 30.33 6.39K
EV to Free Cash Flow
-0.10 2.49 -6.29
EV to Operating Cash Flow
-0.05 1.15 -6.46
Tangible Book Value Per Share
>-0.01 >-0.01 0.03
Shareholders’ Equity Per Share
0.02 0.02 0.04
Tax and Other Ratios
Effective Tax Rate
0.00 0.00 -0.04
Revenue Per Share
<0.01 <0.01 <0.01
Net Income Per Share
>-0.01 >-0.01 -0.24
Tax Burden
0.99 0.99 1.00
Interest Burden
1.02 1.02 1.06
Research & Development to Revenue
0.00 0.00 3.45
SG&A to Revenue
8.34 8.34 1.51K
Stock-Based Compensation to Revenue
<0.01 <0.01 59.11
Income Quality
-3.07 -3.07 0.11
Currency in CAD